Philippe Gaudard

Summary

Country: France

Publications

  1. Gaudard P, Mourad M, Eliet J, Zeroual N, Culas G, Rouvière P, et al. Management and outcome of patients supported with Impella 5.0 for refractory cardiogenic shock. Crit Care. 2015;19:363 pubmed publisher
    ..1 (1.2-14.2); p = 0.02). Impella 5.0 allowed fast weaning of inotropes and might facilitate myocardial recovery. Despite high severity scores at admission, day-28 mortality rate was better than predicated. ..
  2. Colson P, Virsolvy A, Gaudard P, Charrabi A, Corbani M, Manière M, et al. Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: Implications for its safety profile. Pharmacol Res. 2016;113:257-264 pubmed publisher
    ..Terlipressin is a non-selective vasopressin analogue, exhibiting intrinsic agonist properties. Its full V2 receptor agonism may result in renal effects potentially aggravating water retention and hyponatremia of cirrhosis. ..